Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer

Approximately 50% of HER2 positive breast cancer cases are also estrogen receptor (ER) positive. Data supports a role for close cross-talk between the ER and HER2 signaling pathways as an important contributor to the development of de novo or acquired resistance to hormone therapies. Therefore a str...

Descripción completa

Detalles Bibliográficos
Autores principales: Montagna, Emilia, Colleoni, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918494/
https://www.ncbi.nlm.nih.gov/pubmed/31897091
http://dx.doi.org/10.1177/1758835919894105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918494/
https://www.ncbi.nlm.nih.gov/pubmed/31897091
http://dx.doi.org/10.1177/1758835919894105

Ejemplares similares